What's in Recardio, Inc.'s pipeline?

Recardio, Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Recardio, Inc.'s portfolio?

Top competitors by shared drug class: Asan Medical Center, Centre Leon Berard, Chinese Academy of Medical Sciences, Xiamen Amoytop Biotech Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/recardio-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Recardio, Inc. — Portfolio Competitive Intelligence Brief

Recardio, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Dutogliptin + Filgrastim	Dutogliptin + Filgrastim	phase 3	DPP-4 inhibitor + G-CSF receptor agonist	DPP-4 enzyme; G-CSF receptor (CD114)	Cardiovascular, Diabetes

Therapeutic area mix

Cardiovascular, Diabetes · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Asan Medical Center · 1 shared drug class
Centre Leon Berard · 1 shared drug class
Chinese Academy of Medical Sciences · 1 shared drug class
Xiamen Amoytop Biotech Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Recardio, Inc.:

Cite this brief

Drug Landscape (2026). Recardio, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/recardio-inc. Accessed 2026-05-16.